ClinicalTrials.gg
RecruitingNCT06501326Updated Jul 15, 2024

Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease

A Phase 4 interventional study of Liraglutide and Orlistat in Non-alcoholic Fatty Liver Disease and Obesity, sponsored by Affiliated Hospital of Nantong University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Affiliated Hospital of Nantong University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
48th of 89
102 · median 112
Started
2023
with 19 others
Phase 4
11 of 143
3 open now
Primary completion
2024-10
later than 3 of 52 live
Registered
104th of 143
by date

Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 48th largest by planned enrollment of the 89 interventional ones that give a count, is one of 20 that started in 2023, is one of 11 in phase 4, reaches primary completion later than 3 of the 52 other live ones, and was the 104th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

STUDY OBJECTIVE: To explore the clinical efficacy and safety of liraglutide in obesity combined with metabolism-associated fatty liver disease (MAFLD).

INTERVENTION PROGRAM: All subjects underwent dietary control and exercise therapy, and controlled smoking and alcohol consumption. During the 3 months of the trial, men were instructed to follow a diet of 1,500 to 1,800 kcal per day and women followed a diet of 1,200 to 1,500 kcal per day. All three diets included 40 to 55 percent carbohydrates, 15 to 20 percent protein and 20 to 30 percent fat. During the 3-month trial period, subjects performed at least 150 minutes of moderate-intensity exercise per week with an energy expenditure of 1500 kcal/week or more. Other medications containing the same ingredients as orlistat and liraglutide were prohibited during the trial period. After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.

Read the detailed description
  1. Randomization Patients were divided into three groups by lifestyle intervention + orlistat treatment, in lifestyle intervention + liraglutide treatment and in lifestyle intervention + orlistat + liraglutide treatment, and eligible patients were randomized into trial group 1,2 and control group strictly according to the random number method. The ratio of test group 1,2 and control group was 1:1:1.
  2. Name and specification of the intervention / study medication Use: liraglutide injection, 3ml: 18mg (prefilled pen) and orlistat capsules.
  3. Study the intervention program All subjects were treated with dietary control and exercise therapy and controlled smoking and alcohol consumption.During the 3 months of the trial, men were instructed to follow a diet of 1500 to 1800 kcal per day and women followed a diet of 1200 to 1500 kcal per day. All three groups of diets included 40% to 55% carbohydrates, 15% to 20% protein and 20% to 30% fat.During the 3-month trial period, conduct at least 150 minutes of moderate intensity exercise per week, with exercise energy consumption of 1500 kcal / week or more.Other drugs containing the same ingredients of orlistat and liraglutide were prohibited during the trial.After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up.Trial Group 1 was treated with lifestyle intervention plus liraglutide.Trial Group 2 was treated with lifestyle intervention plus liraglutide plus orlistat.Medication regimen: Patients in the test or control groups were treated with liraglutide or (and) orlistat for 3 months from the first day after enrollment. The starting dose of liraglutide was 0.6mg per day, gradually increased to 1.2mg per day after one week, and continued to 1.8mg per day when tolerated. Patients taking orlistat should take 120mg orlistat capsules every day or one hour after a meal, and if one meal is not eaten or the food is not fat, they can be omitted.
  4. Efficacy evaluation index (primary efficacy index and secondary efficacy index) glycosylated hemoglobin, FABP 4, body weight, waist circumference, hip circumference, BMI, and lipid index: TC, TG, HDL-C, LDL-C; Liver fibrosis index: liver hardness, liver fat attenuation (fibro scan detection instrument), body fat volume, visceral fat area (inbody body meter), liver function index: balanced and comparable analysis of ALT and AST before the treatment of the three groups of (1); (2) the change of each level before and after treatment, Test of their respective efficacy; (3) The difference between the three groups after treatment and the difference between the groups and the three groups.
03

Conditions studied

  • Non-alcoholic Fatty Liver Disease
  • Obesity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of Metabolic Associated Fatty Liver Disease(MAFLD);
  2. Clinical diagnosis of Obesity.

Exclusion criteria

Exclusion Criteria:

  1. Medicated Hepatitis and Viral Hepatitis;
  2. Have severe hepatic or renal insufficiency;
  3. have used any weight-loss drug;
  4. History of severe gastrointestinal disorders;
  5. Malignant tumors, diseases, hematologic diseases;
  6. Psychopath;
  7. Women who are pregnant, breastfeeding or preparing for pregnancy;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Active comparator
    lifestyle intervention + orlistat group

    The control group was treated with lifestyle intervention + orlistat until the end of follow-up.

    Drug: Orlistat

  • Experimental
    lifestyle intervention + liraglutide group

    Trial group 1 was treated with lifestyle intervention + liraglutide.

    Drug: Liraglutide

  • Experimental
    lifestyle intervention + liraglutide + orlistat group

    Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.

    Drug: Liraglutide · Drug: Orlistat

Interventions

  • After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.

  • After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.

06

What researchers measure

Primary outcomes

  1. Body weight

    Body weight

    Time frame: Three months

  2. FABP4

    fatty acid-binding protein-4

    Time frame: Three months

  3. BMI

    body mass index

    Time frame: Three months

  4. lipid indices

    TC, TG, HDL-C, LDL-C

    Time frame: Three months

  5. LSM

    liver stiffness measurement

    Time frame: Three months

  6. CAP

    Controlled attenuation parameters

    Time frame: Three months

Secondary outcomes

  1. Waist circumference,

    Waist circumference

    Time frame: Three months

  2. hip circumference

    hip circumference

    Time frame: Three months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Oct 2024, 11 months after the start.

Of 41 non-industry phase 4 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 11 months is below that.

Counting every sponsor, half of 44 studies reached it within 25 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2023
First posted
Jul 15, 2024
StartActual
Nov 1, 2023
Primary completionEst.
Oct 31, 2024
CompletionEst.
Feb 28, 2025
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501326
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Nov 1, 2023
Primary completion
Oct 31, 2024 (estimated)
Completion
Feb 28, 2025 (estimated)
Last update
Jul 15, 2024

Study contacts

GU Yunjuan, doctor
Contact
desette@ntu.edu.cn
15851207860 ext. 86
XIA Jie, master
Contact
desette@ntu.edu.cn
19502555209 ext. 86
GU Yunjuan, doctor
study director · Affiliated Hospital of Nantong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liraglutide · Orlistat

Start the discussion